New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Attention-Deficit/Hyperactivity Disorder
Dyanavel XR Oral Tablets Approved for ADHD
Dyanavel XR tablets will be supplied as 5mg, 10mg, 15mg. and 20mg tablets.
PCPs Not Routinely Recommending Early Behavioral Treatment for ADHD
Only 11 percent of preschoolers with ADHD diagnosis or symptoms received referrals for parent training in behavior management
Viloxazine Under Review for ADHD Treatment in Adults
The Food and Drug Administration has accepted for review the supplemental New Drug Application for viloxazine extended-release for the treatment of attention-deficit hyperactivity disorder in adults. The application is supported by data from a multicenter, randomized, double-blind, placebo-controlled phase 3 trial (ClinicalTrials.gov Identifier: NCT04016779), which assessed the efficacy and safety of viloxazine in 374 adults…
Most Children Experience Fluctuations in ADHD Symptoms
While nearly one in three will experience points of remission of ADHD symptoms, most experience recurrence over time and few outgrow it
Exposure to Prenatal Antipsychotics Seems Safe
No increased risk seen for ADHD, ASD, small for gestational age with prenatal antipsychotics exposure
Azstarys, a Novel ADHD Treatment, Now Available
Azstarys consists of serdexmethylphenidate, a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate.
Prescription Drug Dispensing to Children Down During Pandemic
Percentage changes were −51.3 and −17.4 percent for drug classes typically treating acute infections, chronic diseases
Drug May Curb ‘Sluggish’ Thinking in Some Adults With ADHD
Lisdexamfetamine found to reduce symptoms of sluggish cognitive tempo in small group of adults with ADHD
Adhansia XR Labeling Updated With Additional Clinical Data
The sNDA approval was based on data from a phase 3 Adult Laboratory Classroom study that assessed the efficacy and safety of Adhansia XR in adults diagnosed with ADHD.
